Harrow (NASDAQ:HROW - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Harrow to post earnings of $0.02 per share and revenue of $57.00 million for the quarter. Harrow has set its FY 2025 guidance at EPS.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, analysts expect Harrow to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Harrow Trading Up 3.4 %
NASDAQ:HROW traded up $0.81 on Friday, hitting $24.40. The stock had a trading volume of 1,281,092 shares, compared to its average volume of 512,477. The company has a fifty day moving average price of $24.79 and a two-hundred day moving average price of $32.82. Harrow has a 1-year low of $10.20 and a 1-year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a market cap of $895.11 million, a price-to-earnings ratio of -25.96 and a beta of 0.41.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. B. Riley cut their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and set a $57.00 price objective on shares of Harrow in a research report on Monday, March 31st.
Read Our Latest Report on Harrow
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Articles
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
